Olmetec and Tasigna drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Olmetec (olmesartan medoxomil) and Tasigna (nilotinib hydrochloride monohydrate). Common drug interactions include anaemia among females and angina pectoris among males.

The phase IV clinical study analyzes what interactions people have when they take Olmetec and Tasigna. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.

What is Tasigna?

Tasigna has active ingredients of nilotinib hydrochloride monohydrate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 31,535 Tasigna users. Check the latest studies of Tasigna.

On Jul, 14, 2026

25 people who take Olmetec and Tasigna together, and have interactions are studied.

What are the common drug interactions of Olmetec and Tasigna, by gender? *:

female:

Anaemia (lack of blood)
Arteriosclerosis (thickening and hardening of arteries)
Haemoglobin decreased
Haemorrhage (bleeding)
Infection
Thrombocytopenia (decrease of platelets in blood)
Intermittent claudication
Diplegia (paralysis of corresponding parts on both sides of the body)
Duodenal ulcer haemorrhage (bleeding duodenal ulcer)
Fall

male:

Angina pectoris (chest pain due to ischemia of the heart muscle)
Pruritus (severe itching of the skin)
Gynaecomastia (enlargement of the gland tissue of the male breast)
Hyperglycaemia (high blood sugar)
Rash papular (redness with papule)
Neutropenia (an abnormally low number of neutrophils)
White blood cell count decreased
Blood bilirubin unconjugated increased
Haemoglobin decreased
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)

What are the common drug interactions of Olmetec and Tasigna, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Angina pectoris (chest pain due to ischemia of the heart muscle)
Foot fracture
Ischaemic stroke (stroke; caused by an interruption in the flow of blood to the brain)
Pain in extremity

40-49:

n/a

50-59:

Angina pectoris (chest pain due to ischemia of the heart muscle)
Gamma-glutamyltransferase increased
Hyperuricaemia (level of uric acid in the blood that is abnormally high)
Blood bilirubin increased
Blood bilirubin unconjugated increased
Pleural effusion (water on the lungs)
Pyrexia (fever)

60+:

Anaemia (lack of blood)
Pruritus (severe itching of the skin)
Haemoglobin decreased
Hyperglycaemia (high blood sugar)
Rash papular (redness with papule)
Neutropenia (an abnormally low number of neutrophils)
White blood cell count decreased
Dyspnoea (difficult or laboured respiration)
Fall
Oedema peripheral (superficial swelling)

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 25 people, 100.00%
Hepatic Function Abnormal: 3 people, 12.00%
Glucose Tolerance Impaired (blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis): 3 people, 12.00%
Gastric Ulcer (stomach ulcer): 3 people, 12.00%
Thyroid Diseases: 2 people, 8.00%
Insomnia (sleeplessness): 2 people, 8.00%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 2 people, 8.00%
Essential Hypertension (primary hypertension): 2 people, 8.00%
Diabetes: 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Olmetec and Tasigna?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously